Federal Register / Vol. 75, No. 86 / Wednesday, May 5, 2010 / Notices 24719 

ACTION: Notice of public meeting; 

request for comments. 

The Food and Drug Administration 

(FDA) is announcing a public meeting 

entitled ‘‘Town Hall Discussion With the 

Director of the Center for Devices and 

Radiological Health and Other Senior 

Center Management.’’ The purpose of 

this meeting is to present the Center for 

Devices and Radiological Health (CDRH) 

fiscal year (FY) 2010 priorities. In 

addition, FDA is interested in engaging 

in discussions about issues that are of 

importance to the medical device 

industry. 

Date and Time: The public meeting 

will be held on June 22, 2010, from 9 

a.m. to 5 p.m. 

Location: The public meeting will be 

held at the Hilton Boston/Woburn, Two 

Forbes Rd., Woburn, MA 01801. The 

meeting will not be videotaped or Web 

cast. 

Contact: Heather Howell, Center for 

Devices and Radiological Health, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 66, rm. 4320, 

Silver Spring, MD 20993, 301–796– 

5718, e-mail: 

heather.howell@fda.hhs.gov. 

Registration and Requests for Oral 

Presentations: If you wish to attend the 

public meeting, you must register online 

at: http://www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

ucm206671.htm. Provide complete 

contact information for each attendee, 

including name, title, company or 

organization, address, e-mail, and 

telephone number. Registration requests 

must be received by 5 p.m. on 

Wednesday, June 9, 2010. 

If you wish to make an oral 

presentation during any of the sessions 

at the meeting (see section II of this 

document), you must indicate this at the 

time of registration. FDA will do its best 

to accommodate requests to speak. 

Individuals and organizations with 

common interests are urged to 

consolidate or coordinate their 

presentations, and to request time for a 

joint presentation. FDA will determine 

the amount of time allotted to each 

presenter and the approximate time that 

each oral presentation is scheduled to 

begin. 

Registration is free and will be on a 

first-come, first-served basis. Early 

registration is recommended because 

seating is limited. FDA may limit the 

number of participants from each 

organization based on space limitations. 

Registrants will receive confirmation 

once they have been accepted. Onsite 

registration on the day of the public 

meeting will be provided on a spaceavailable basis beginning at 8 a.m. 

If you need special accommodations 

due to a disability, please contact Susan 

Monahan at 301–796–5661 or e-mail: 

susan.monahan@fda.hhs.gov at least 7 

days in advance of the meeting. 

Comments: FDA is holding this public 

meeting to share information and 

discuss issues of importance to the 

medical device industry. CDRH is 

specifically interested in addressing the 

following question: What mechanism(s) 

would you prefer or suggest for FDA to 

engage with industry? The deadline for 

responding to this question and for 

submitting other comments related to 

this public meeting is Wednesday, June 

9, 2010. 

Regardless of attendance at the public 

meeting, interested persons may submit 

written or electronic comments. Submit 

written comments to the Division of 

Dockets Management (HFA–305), Food 

and Drug Administration, 5630 Fishers 

Lane, rm. 1061, Rockville, MD 20852. 

Submit electronic comments to http:// 

www.regulations.gov. Submit a single 

copy of electronic comments or two 

paper copies of any mailed comments, 

except that individuals may submit one 

paper copy. Comments are to be 

identified with the docket number 

found in brackets in the heading of this 

document. Received comments may be 

seen in the Division of Dockets 

Management between 9 a.m. and 4 p.m., 

Monday through Friday. 

SUPPLEMENTARY INFORMATION: 

I. Background 

CDRH has announced four priority 

areas of activity for FY 2010, each of 

which presents significant opportunities 

to improve CDRH’s effectiveness in 

fulfilling our public health mission. 

More information, including specific 

goals and actions associated with each 

priority, is available under ‘‘CDRH 

Strategic Planning’’ at http:// 

www.fda.gov/AboutFDA/CentersOffices/ 

CDRH. 

II. Public Meeting 

The objective of this public meeting is 

to present CDRH’s FY 2010 priorities. In 

addition, FDA is interested in engaging 

in discussions about issues that are of 

importance to the medical device 

industry. CDRH wishes to obtain 

feedback/ideas for facilitating two-way 

communication between CDRH and the 

medical device industry. 

The meeting will open with an 

introduction of CDRH Senior Staff in 

attendance. Following introductions, Dr. 

Jeffrey Shuren, the Director of CDRH, 

will present the FY 2010 CDRH 

priorities. Industry representatives and 

other members of the public will then 

be given the opportunity to present 

comments to CDRH Senior Staff. 

Attendees from CDRH may respond to 

questions presented by industry and 

other members of the public. 

In advance of the meeting, additional 

information, including a meeting agenda 

with a speakers’ schedule, will be made 

available on the Internet. This 

information will be placed on file in the 

public docket (docket number found in 

brackets in the heading of this 

document), which is available at http:// 

www.regulations.gov. This information 

will also be available at http:// 

www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

default.htm (select the appropriate 

meeting from the list). 

III. Transcripts 

Please be advised that as soon as a 

transcript is available, it will be 

accessible at http:// 

www.regulations.gov. It may be viewed 

at the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD. A transcript will 

also be available in either hardcopy or 

on CD–ROM, after submission of a 

Freedom of Information request. Written 

requests are to be sent to Division of 

Freedom of Information (HFI–35), Office 

of Management Programs, Food and 

Drug Administration, 5600 Fishers 

Lane, rm. 6–30, Rockville, MD 20857. 

Dated: April 30, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–10563 Filed 5–4–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0002] 

Withdrawal of Approval of New Animal 

Drug Applications; Coumaphos; 

Novobiocin; Buquinolate and 

Lincomycin 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is withdrawing 

approval of three new animal drug 

applications (NADAs). In a final rule 

published elsewhere in this issue of the 

Federal Register, FDA is amending the 

animal drug regulations to remove 

portions reflecting approval of the single 

NADA of the three that is codified. 

DATES: Withdrawal of approval is 

effective May 17, 2010. 


sroberts on DSKD5P82C1PROD with NOTICES
24720 Federal Register / Vol. 75, No. 86 / Wednesday, May 5, 2010 / Notices 

FOR FURTHER INFORMATION CONTACT: John 

Bartkowiak, Center for Veterinary 

Medicine (HFV–212), Food and Drug 

Administration, 7519 Standish Pl., 

Rockville, MD 20855, 240–276–9079, e– 

mail: john.bartkowiak@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

following sponsors have requested that 

FDA withdraw approval of the three 

NADAs listed in Table 1: 

TABLE 1. 

Sponsor NADA No./Product 

(Established Name of Drug) 

21 CFR Cite 

(Sponsor’s Drug Labeler Code) 

Pharmacia & Upjohn Co., a Division of 

Pfizer, Inc., 235 East 42d St., New York, 

NY 10017 

NADA 13–467/ALBAMIX Susceptibility Disks 

(novobiocin) 

Not codified 

Pharmacia & Upjohn Co., a Division of 

Pfizer, Inc., 235 East 42d St., New York, 

NY 10017 

NADA 45–738/LINCOMIX/BONAID 

(lincomycin/buquinolate) 

Not codified 

Purina Mills, Inc., P.O. Box 66812, St. 

Louis, MO 63166–6812 

NADA 42–117/Purina 6 Day Worm-Kill Concentrate 

(coumaphos) 

558.185 (017800) 

Therefore, under authority delegated 

to the Commissioner of Food and Drugs 

and redelegated to the Center for 

Veterinary Medicine, and in accordance 

with § 514.116 Notice of withdrawal of 

approval of application (21 CFR 

514.116), notice is given that approval 

of NADAs 13–467, 42–117, and 45–738, 

and all supplements and amendments 

thereto, is hereby withdrawn, effective 

May 17, 2010. 

In a final rule published elsewhere in 

this issue of the Federal Register, FDA 

is amending the animal drug regulations 

to reflect the withdrawal of approval of 

NADA 42–117. 

Dated: April 30, 2010. 

Bernadette Dunham, 

Director, Center for Veterinary Medicine. 

[FR Doc. 2010–10567 Filed 5–4–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HOMELAND 

SECURITY 

United States Immigration and 

Customs Enforcement 

Agency Information Collection 

Activities: Extension of an Existing 

Information Collection; Comment 

Request 

ACTION: 60-Day Notice of Information 

Collection for Review; Form I–333, 

Obligor Change of Address. 

The Department of Homeland 

Security, U.S. Immigration and Customs 

Enforcement (USICE), has submitted the 

following information collection request 

for review and clearance in accordance 

with the Paperwork Reduction Act of 

1995. The information collection is 

published to obtain comments from the 

public and affected agencies. Comments 

are encouraged and will be accepted for 

sixty days until July 6, 2010. 

Written comments and suggestions 

regarding items contained in this notice, 

and especially with regard to the 

estimated public burden and associated 

response time should be directed to the 

Department of Homeland Security 

(DHS), Joseph M. Gerhart, Chief, 

Records Management Branch, U.S. 

Immigration and Customs Enforcement, 

500 12th Street, SW., Room 3138, 

Washington, DC 20536; (202) 732–6337. 

Comments are encouraged and will be 

accepted for sixty days until July 6, 

2010. Written comments and 

suggestions from the public and affected 

agencies concerning the proposed 

collection of information should address 

one or more of the following four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(2) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Overview of this information 

collection: 

(1) Type of Information Collection: 

Extension of a currently approved 

information collection. 

(2) Title of the Form/Collection: 

Obligor Change of Address. 

(3) Agency form number, if any, and 

the applicable component of the 

Department of Homeland Security 

sponsoring the collection: Form I–333, 

U.S. Immigration and Customs 

Enforcement. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: Individual or 

Households, Business or other nonprofit. The information collected on the 

Form I–333 is necessary for U.S. 

Immigration and Customs Enforcement 

(ICE) to provide immigration bond 

obligors a standardized method to notify 

ICE of address updates. Upon receipt of 

the formatted information records will 

then be updated to ensure accurate 

service of correspondence between ICE 

and the obligor. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: 12,000 responses at 15 minutes 

(.25 hours) per response. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: 3,000 annual burden hours. 

Requests for a copy of the proposed 

information collection instrument, with 

instructions; or inquiries for additional 

information should be requested via email to: forms.ice@dhs.gov with ‘‘ICE 

Form I–333’’ in the subject line. 

Dated: April 28, 2010. 

Joseph M. Gerhart, 

Branch Chief, Records Management Branch, 

U.S. Immigration and Customs Enforcement, 

Department of Homeland Security. 

[FR Doc. 2010–10546 Filed 5–4–10; 8:45 am] 

BILLING CODE 9111–28–P 


sroberts on DSKD5P82C1PROD with NOTICES